MELATONIN AND MALIGNANT MELANOMA

褪黑激素和恶性黑色素瘤

• 批准号: 5218098
• 负责人: WILLIAM A. ROBINSON
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5218098
• 关键词: clinical research; hormone therapy; human subject; human therapy evaluation; melanoma; melatonin; neoplasm /cancer chemotherapy

Patients with advanced measurable metastatic malignant melanoma are treated with oral melantonin. The dose is escalated by 25 per cent in groups of 3 patients starting at 75 mg/m2. Patients are then followed for response and toxicity with particular emphasis on measurement of gonadotropin and thyroid hormones.

晚期可测量转移性恶性黑色素瘤患者 用口服黑素进行治疗年剂量增加25% 每组3名患者，从75 mg/m2开始。然后对患者进行随访， 反应和毒性，特别强调测量 促性腺激素和甲状腺激素。